Abstract

THERAPEUTIC SIGNIFICANCE OF VIRECHANOPAGA DASAIMANI: CLASSICAL EVIDENCE AND MODERN SCIENTIFIC CORRELATION

Dr. Vasagiri Srujan*, Dr. T. Alekhya, Dr. Arundhathy C. Nair

Abstract

Background: Panchasat Mahakashayas constitute a unique therapeutic classification described in the Charaka Samhita, wherein drugs possessing similar pharmacological actions are grouped together. Among these, Virechanopaga Dasaimani comprises ten adjuvant drugs that support and enhance the efficacy of virechana karma, the principal bio-purificatory therapy for the elimination of aggravated Pitta dosha. Although these drugs are not primary purgatives, they play an important role in facilitating safe, effective, and patient-friendly therapeutic purgation. Objective: To critically evaluate the classical concepts, pharmacodynamic properties, therapeutic significance, and probable physiological mechanisms of Virechanopaga Dasaimani with contemporary scientific correlation. Methods: A classical narrative review was conducted using primary Ayurvedic sources, including Charaka Samhita, Ashtanga Hridaya, and major Nighantus, supported by standard Dravyaguna and Panchakarma literature. Pharmacodynamic attributes such as Rasa, Guna, Veerya, Vipaka, Dosha Karma, and available phytochemical and pharmacological evidence were compiled and critically analyzed. Results: Virechanopaga Daśaimani consists of ten drugs—Draksha (Vitis vinifera Linn.), Kasmarya (Gmelina arborea Roxb.), Parushaka (Grewia asiatica Linn.), Abhaya (Terminalia chebula Retz.), Amalaki (Emblica officinalis Gaertn.), Vibhitaki (Terminalia bellirica Roxb.), Kuvala (Zizyphus sativa Gaertn.), Badara (Zizyphus jujuba Lam.), Karkandhu (Ziziphus nummularia W. & A.), and Peelu (Salvadora persica Linn.). The group predominantly exhibits Madhura and Amla Rasa, Guru, Snigdha, and Sara Gunas, Ushna Veerya, and Madhura Vipaka, with most drugs possessing Pitta-samana or Tridosha-samana actions. Bhedana Karma and Sara Guna appear to be the principal attributes responsible for their virechanopaga activity. Collectively, these drugs may act synergistically with primary virechana drugs, facilitate elimination of residual doshas, minimize adverse effects of purgation, preserve dhatu and ojas, and improve patient acceptability. Their nourishing and relatively mild nature also suggests suitability for use in debilitated individuals, children, and seasonal purification regimens. Furthermore, the drugs may be employed either individually or in combination according to the clinical condition. Conclusion: Virechanopaga Dasaimani represents a strategically designed adjuvant group that enhances the safety, efficacy, and therapeutic outcomes of Virechana karma. The classical concepts underlying these drugs correlate with modern perspectives on gastrointestinal regulation, mucosal protection, and restorative pharmacology. Further experimental and clinical studies are warranted to validate their synergistic role and strengthen the evidence base for their application in contemporary Panchakarma practice.

Keywords: Virechana karma, Panchakarma, Dravyaguna, Adjuvant drugs.